Back

MannKind shares fall after inhaled GLP-1 licensing deal with Rose Pharma

Verifying
  • MannKind and Rose Pharma signed a licensing and collaboration agreement for an inhaled GLP-1 program.
  • MannKind shares traded 0.1% below both the 20-day and 50-day SMAs, each at $4.04.
  • Rose Pharma received an exclusive worldwide license for ROSE-010 Technosphere development and commercialization.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.